Eyenovia MiDD Usability Study

Eyenovia

Status

Completed

Conditions

Intraocular Pressure

Treatments

Drug: Latanoprost

Study type

Interventional

Funder types

Industry

Identifiers

NCT03480906

EYN-POC-PG-21

Details and patient eligibility

About

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy patients without significant ocular pathology and mean unmedicated diurnal intraocular pressure (IOP) in the range of of 17-27 mmHg
Willing to forego use of contact lenses during study period
Presence of cognition an dexterity necessary to follow MiDD drug administration instructions
Female subjects must be 1-year postmenopausal, surgically sterilized, or if of childbearing potential, have a negative serum pregnancy test

Exclusion criteria

Prior clinically significant ocular history or abnormal eye exam
Use of ocular medication within 30 days of screening
Use of oral steroid within 30 days of screening, or anticipated need for ocular steroid treatment during study period
History of drug or alcohol abuse within 1 year of screening
Lid squeezer
Presence of disabling arthritis or limited motor coordination that would limit self-handling of the MiDD
Participation in any interventional study of an investigational drug or device within 30 days of screening